Abstract:Aldo-keto reductase 1C3(AKR1C3) is a potential target for the treatment of acute myeloid leukaemia and T-cell acute lymphoblastic leukaemia. In this study, pharmacophore models, molecular docking and virtual screening of target prediction were used to find a potential AKR1C3 inhibitor. Firstly, eight bacteriocin derivatives(Z1–Z8) were selected as training sets to construct 20 pharmacophore models. The best pharmacophore model MODEL_016 was obtained by Decoy test(the enrichment degree was 21.5117, and the fitting optimisation degree was 0.9668). Secondly, MODEL_016 was used for the virtual screening of ZINC database. Thirdly, the hit 83256 molecules were docked into the AKR1C3 protein. Compared to the total scores and interactions between compounds and protein, 16532 candidate compounds with higher docking scores and interactions with important residues PHE306 and TRP227 were screened. Lastly, eight compounds(A1–A8) that had good absorption, distribution, metabolism, excretion and toxicity(ADMET) properties were obtained by target prediction. Compounds A3 and A7 with high total score and good target prediction results were selected for <i>in vitro</i> biological activity test, whose IC<sub>50</sub> values were 268.3 and 88.94 µmol/L, respectively. The results provide an important foundation for the discovery of novel AKR1C3 inhibitors. The research methods used in this study can also provide important references for the research and development of new drugs.

Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10

Design and Synthesis of Polyhydroxy Steroids As Selective Inhibitors Against AKR1B10 and Molecular Docking.

Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors

Correction to Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy Against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.

In silico study of novel alpha tocopheroids as effective inhibitors of aldo-keto reductase 1c3 (AKR1C3) enzyme

Investigation of the Potential of Bile Acid Methyl Esters as Inhibitors of Aldo‐keto Reductase 1C2: Insight from Molecular Docking, Virtual Screening, Experimental Assays and Molecular Dynamics

Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment

Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer

Design, Synthesis and Biological Evaluation of Novel Androst-3,5-diene-3-carboxylic Acid Derivatives As Inhibitors of 5Α-Reductase Type 1 and 2

Inhibitor Selectivity Between Aldo – Keto Reductase Superfamily Members AKR 1 B 10 and AKR 1 B 1 : Role of Trp 112 ( Trp 111 )

Design, Synthesis and Biological Evaluation of Novel 3-Oxo-4-oxa-5α-androst-17β-amide Derivatives As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment

Overview of AKR1C3: Inhibitor Achievements and Disease Insights.

Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors As Chemotherapeutic Potentiators for Cancer Drug Resistance.

Design, Synthesis, and Biological Evaluation of Novel Androst-17Β-amide Structurally Related Compounds As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

In Vitro CAPE Inhibitory Activity Towards Human AKR1C3 and the Molecular Basis.

Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3

Catalytic characteristics of AKR1C1-AKR1C4 and AKR1C9 on oxymesterone

Therapeutic potential of targeting AKR1C2 in the treatment of prostate cancer

Study of Aldo-keto Reductase 1C3 Inhibitor with Novel Framework for Treating Leukaemia Based on Virtual Screening and In vitro Biological Activity Testing

Structural Basis for the Inhibition of AKR1B10 by Caffeic Acid Phenethyl Ester (CAPE).